SCHEDULE 13G: Farallon Capital and Affiliates Disclose 7.9% Passive Stake in Beta Bionics, Inc.

Farallon Capital Management and its affiliated entities, along with key individuals, have disclosed a collective beneficial ownership of 7.9% of Beta Bionics, Inc.'s common stock, held as a passive investment.

Summary

• Farallon Capital Management, L.L.C. and its various affiliated funds and entities, including Zone Healthcare Holdings, LLC, have filed a Schedule 13G indicating their beneficial ownership in Beta Bionics, Inc.
• The aggregate beneficial ownership reported by the Farallon Individual Reporting Persons (managing members/senior managing members) is 3,427,220 shares of Beta Bionics, Inc. Common Stock.
• This stake represents 7.9% of the total class of Beta Bionics, Inc. Common Stock.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Beta Bionics, Inc.
• Zone Healthcare Holdings, LLC directly holds 3,277,220 shares, representing 7.6% of the class.
• Farallon Capital Management, L.L.C. also reports beneficial ownership of 3,277,220 shares, or 7.6%, due to its role as manager of Zone Healthcare Holdings, LLC.
• Various Farallon Capital limited partnerships collectively hold additional shares, with Farallon Partners, L.L.C. reporting 143,670 shares (0.3%) due to its general partner role.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, indicating a neutral sentiment. While the investment itself could be seen as positive, the filing contains no forward-looking statements or operational details to assess sentiment beyond the fact of the investment.

Positives

• A significant investment by Farallon Capital Management and its affiliates, a prominent investment firm, indicates their confidence in Beta Bionics, Inc.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a prominent investment firm like Farallon Capital may be viewed positively, potentially signaling institutional confidence in Beta Bionics, Inc.

Next Steps

• The reporting persons are responsible for timely filing of subsequent amendments to this Schedule 13G if their beneficial ownership changes.

Key Dates

Keywords

Beta Bionics Inc., Farallon Capital Management, Schedule 13G, beneficial ownership, common stock, investment, passive stake, SEC filing, institutional investor